Table 3 Subgroup analysis in countries with low prevalence of HCV infection
Outcome | Studies | HR/OR (95%CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|
I2% | P value | ||||
Impact of HCV infection | |||||
Overall survival | 8 | 1.59 (1.16–2.17) | 0.004 | 16 | 0.31 |
Progression-free survival | 6 | 1.45 (1.10–1.90) | 0.008 | 0 | 0.52 |
Overall response rate | 5 | 0.70 (0.49–1.00) | 0.05 | 0 | 0.59 |
Hepatic dysfunction | 5 | 3.87 (1.60–9.36) | 0.003 | 76 | 0.002 |
Age of onset | 4 | 1.97 (1.18–3.28) | 0.01 | 4 | 0.37 |
Advanced disease stage | 10 | 1.22 (0.98–1.52) | 0.07 | 28 | 0.18 |
Presence of B symptom | 4 | 0.80 (0.53–1.21) | 0.30 | 47 | 0.13 |
Elevated LDH level | 6 | 1.54 (1.16–2.04) | 0.003 | 26 | 0.24 |
H-I/H risk | 8 | 1.16 (0.89–1.51) | 0.26 | 0 | 0.52 |
Spleen involvement | 5 | 2.48 (1.65–3.74) | < 0.0001 | 0 | 0.63 |
Liver involvement | 7 | 2.04 (1.32–3.15) | 0.001 | 17 | 0.30 |
Bone marrow involvement | 8 | 0.98 (0.72–1.34) | 0.90 | 0 | 0.46 |